RxDoctor Payments Data

Omer Iftikhar

Interventional Cardiology · Slidell, LANPI 1861832073

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (57.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Medtronic at 28.4% of the total. Reporting peaked in 2022 at $9,039 and has fallen 67.7% since, to $2,917 in 2025.

$21,839in general payments, 2019–2025

Across 247 payments — averaging $88.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Penumbra, Inc.$4K
  • Boston Scientific$3K
  • Edwards Lifesciences$2K
  • Abbott$2K
  • W. L. Gore & Associates, Inc.$933
  • plus $3K from 24 others

What the payments were for

  • Travel & lodging$12,61058%
  • Food & beverage$8,81140%
  • Education$4182%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,839 in reported general payments places this provider in the 70th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$43,078
Medicare patients
201
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban110$105,529
XareltoRivaroxaban26$21,745
Repatha SureclickEvolocumab26$21,618
EntrestoSacubitril/Valsartan17$17,036
Colchicine17$1,616
Metoprolol Succinate137$1,351
Atorvastatin Calcium142$1,253
Ezetimibe95$1,211
ClopidogrelClopidogrel Bisulfate49$435
Carvedilol65$406
Lisinopril66$405
Rosuvastatin Calcium36$399
Amlodipine Besylate73$391
Losartan Potassium40$371
Cilostazol22$361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$30$21,74526 claims
NovartisEntresto$102$17,03617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →